Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 3×
“We thank the Pfizer-BioNTech clinical trial C4591001 and NCT04368728 participants from whom the post-immunization human sera were obtained.”
InfluentialSelf-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · cited 1×
“Plaque reduction neutralization testing The 50% plaque-reduction neutralization titer (PRNT50) was measured for each serum as previously reported (Muruato et al., 2020; Walsh et al., 2020).”
Self-citationSix Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Self-citationSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640 · cited 1×
“While the Beta variant exhibited the neutralization reduction among all tested variants (Liu et al., 2021a; Liu et al., 2021b; Cell Ho Liu et al., 2021c), high efficacy against Beta was observed (Thomas et al., 2021).”
Self-citationSpike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558 · cited 4×
“…GISAID EPI_ISL_6640916 N/A Oligonucleotides Primer CoV19-N2-F (TTACAAACATTGGCCGCAAA) Plante et al., 2021 N/A Primer CoV19-N2-R (GCGCGACATTCCGAAGAA) Plante et al., 2021 N/A Primers for Omicron-spike mutagenesis Zou et al., 2022 NA Recombinant DNA pUC57-CoV2-F1 Xie et al., 2020 N/A pCC1-CoV2-F2 Xie…”
InfluentialSelf-citationCele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
An Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647 · cited 6×
“…CoV19-N2-R (GCGCGACATTCCGAAGAA) Plante et al., 2021 N/A Primers for Omicron-spike mutagenesis Zou et al., 2022 NA Recombinant DNA pUC57-CoV2-F1 Xie et al., 2020 N/A pCC1-CoV2-F2 Xie et al., 2020 N/A pCC1-CoV2-F3 Xie et al., 2020 N/A pUC57-CoV2-F4 Xie et al., 2020 N/A pCC1-F567-Omicron spike…”
InfluentialSelf-citationXie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628
Self-citationNeutralizing Activity of BNT162b2-Elicited Serum
Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537 · cited 3×
“While the Beta variant exhibited the neutralization reduction among all tested variants (Liu et al., 2021a; Liu et al., 2021b; Cell Ho Liu et al., 2021c), high efficacy against Beta was observed (Thomas et al., 2021).”
Self-citationSARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Falsey, A. R., Frenck, R. W., Walsh, E. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Bailey, R., Swanson, K. A., Xu, X., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2113468 · Cited by 361 · cited 3×
“While the Beta variant exhibited the neutralization reduction among all tested variants (Liu et al., 2021a; Liu et al., 2021b; Cell Ho Liu et al., 2021c), high efficacy against Beta was observed (Thomas et al., 2021).”
Self-citation
Cited by
Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H. C., Ren, P., Xie, X., & Shi, P. (2023) · Nature Medicine · doi:10.1038/s41591-022-02162-x · Cited by 423
Self-citationDelta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant
Liu, Y., Liu, J., Johnson, B. A., Xia, H., Ku, Z., Schindewolf, C., Widen, S. G., An, Z., Weaver, S. C., Menachery, V. D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110829 · Cited by 413
Self-citationQu, P., Evans, J. P., Faraone, J. N., Zheng, Y.-M., Carlin, C., Anghelina, M., Stevens, P., Fernandez, S., Jones, D., Lozanski, G., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2022.11.012 · Cited by 261
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
Goel, R. R., Painter, M. M., Lundgreen, K. A., Apostolidis, S. A., Baxter, A. E., Giles, J. R., Mathew, D., Pattekar, A., Reynaldi, A., Khoury, D. S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.009 · Cited by 207
“…be at least partially boosted in the short term (up to 1 month) after a 3rd vaccine dose (Muecksch et al., 2022; Muik et al., 2022; Schmidt et al., 2021b; Xia et al., 2022), suggesting that immunological memory generated by 2-dose vaccination has some reactivity against the Omicron spike protein.”
Early computational detection of potential high-risk SARS-CoV-2 variants
(2023) · doi:10.1016/j.compbiomed.2023.106618 · Cited by 46
Metadata
- Authors
- Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M., Cooper, D., Muik, A., Jansen, K. U., Xie, X., Swanson, K. A., & Shi, P.-Y.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 30
- Issue
- 4
- Pages
- 485-488.e3
- ISSN
- 1931-3128 (ISSN-L)
- OpenAlex
- W4213143712
- Cited by
- 97
- References
- 11
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. https://app.cochat.ai/papers/10.1016/j.chom.2022.02.015
- The paper
- Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M., Cooper, D., Muik, A., Jansen, K. U., Xie, X., Swanson, K. A., & Shi, P.-Y. (2022). Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2022.02.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.